A director at Bristol Myers Squibb Co sold 56,000 shares at 47.330USD and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years...
A director at Becton Dickinson & Co bought 5,250 shares at 191.570USD and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...
Moody's Ratings commented that Becton, Dickinson and Company's (BD, Baa2 stable) separation of its Biosciences and Diagnostic Solutions businesses through a Reverse Morris Trust (RMT) structure is credit negative. The transaction will reduce BD's scale and earnings while increasing its financial lev...
S&P 500 and Nasdaq 100 Testing Prior 2022 Highs Since late-February (2/25/25 Compass) we expected an 8-10% pullback to provide a buying opportunity. But that all changed in last week's Compass (4/1/25), when we downgraded our outlook to bearish/cautious, citing several concerning developments (SPX and QQQ failure at 200-day MAs, bear flag breakdowns across major indexes targeting 5100-5200 on SPX, high yield spreads widening above 355bps, major tops on market leaders NVDA and META, semiconducto...
Near-Term Downside Likely Following False Breakouts Our long-term outlook remains bullish as long as the S&P 500 remains above 5770-5850 and 5600-5670 (worst case), and we are buyers at these levels. With that said, we see potential for near-term downside as the S&P 500, Nasdaq 100 (QQQ), and FANG+ (FNGS) (1) could not decisively break out to new highs, (2) display bearish false breakouts, (3) have fallen back into their 2+ month trading ranges, (4) are violating their 1+ month uptrends, and (5...
S&P 500 Holding Above Prior Breakout Level Yet Again As discussed throughout the first half of January, we continue to believe that tariffs will mostly be used as a negotiation tactic, and much like Trump's prior presidency, will be much less impactful than feared. We reiterated this in yesterday's pre-market ETF Pathfinder, also noting "we anticipate the Canada/Mexico tariffs to be resolved relatively quickly, and therefore we view the latest pullback as a buying opportunity." Sure enough, bot...
Moody's Ratings (Moody's) affirmed the ratings of Bristol-Myers Squibb Company ("Bristol") including the A2 senior unsecured long-term ratings, the Prime-1 commercial paper rating, the A2 rating on the senior unsecured revolving credit facility, the (P)A2 senior unsecured shelf rating, the (P)A3 sub...
Moody's Ratings (Moody's) commented that Becton, Dickinson and Company's (Baa2 stable) announcement that it had reached an agreement to resolve the vast majority of its US product liability lawsuits involving hernia repair devices is credit negative. Per the settlement terms, Becton will make paymen...
Moody's Ratings (Moody's) commented that Becton, Dickinson and Company's (Baa2 stable) announcement that it had reached an agreement to resolve the vast majority of its US product liability lawsuits involving hernia repair devices is credit negative. Per the settlement terms, Becton will make paymen...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.